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ABSTRACT 11 
Most current diagnostic tests for transmissible spongiform encephalopathies (TSE) rely on the 12 
presence of PK-resistant PrPSc (PrP-res) in post-mortem tissues as indicative of TSE disease. 13 
However, a number of studies have highlighted a discrepancy between TSE infectivity and PrP-14 
res levels in both natural and experimental cases of TSE disease. Previously we have shown high 15 
TSE infectivity levels in the brain tissue of mice that have a clinical TSE disease with associated 16 
vacuolar pathology but little or no PrP-res detectable. Here the levels of TSE infectivity and PrP-17 
res within a peripheral tissue of this mouse model were investigated. Biochemical analysis 18 
identified low levels of PrP-res were present in the spleen tissue in comparison to levels 19 
observed in the spleen of mice infected with ME7 or 79A. However, upon sub-passage of brain 20 
and spleen tissue from clinically ill mice with little or no PrP-res detectable, similar short 21 
incubation periods to disease were observed, indicating that infectivity levels were similarly high 22 
in both tissues. Thus the discrepancy between PrP-res and TSE infectivity was also present in the 23 
peripheral tissues of this disease model. This result indicates that peripheral tissues can contain 24 
higher levels of infectivity given the correct combination of host species, PrP genotype and TSE 25 
agent. Therefore the assumption that levels of peripheral infectivity are lower than those in the 26 
central nervous system is not always correct and could have implications for current food safety 27 
regulations. 28 
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INTRODUCTION 29 
Transmissible spongiform encephalopathies (TSEs) are a group of fatal, neurodegenerative 30 
diseases that can affect both humans and animals. TSEs can be sporadic, familial or acquired 31 
diseases. The nature of the infectious agent remains unknown; however the prion hypothesis 32 
proposes that a misfolded form (PrPSc) of the host glycoprotein, PrPC, acts as the sole or main 33 
component of the infectious agent in TSE disease (1). The abnormal, disease associated form is 34 
increased in β-sheet content, detergent insoluble and partially resistant to proteinase K (PK) 35 
digestion. Based on the prion hypothesis the majority of current diagnostic tests rely on the 36 
protease-resistance of the disease-associated form (PrP-res) to identify cases of TSE disease 37 
post-mortem. However, a number of experimental cases of TSE disease have been identified in 38 
which PrP-res was not detectable, including wild-type mice infected with BSE (2) and wild-type 39 
mice infected with hamster scrapie (3). In both cases, sub-passage of the tissue confirmed the 40 
presence of TSE infectivity despite the absence of PrP-res.  41 
The highest levels of TSE infectivity are found in tissues of the central nervous system (CNS) of 42 
infected animals. However, the infectious agent has also been demonstrated to be present in 43 
peripheral tissues of some animals, specifically in the lymphoreticular system (LRS) including 44 
the spleen, with the presence of PrP-res and/or TSE infectivity during disease pathogenesis 45 
dependent upon host species, PrP genotype and strain of TSE agent. In scrapie-infected sheep, 46 
VRQ/VRQ homozygotes have PrP-res deposition in the spleen whilst other genotypes, 47 
ARR/ARR and VRQ/ARR do not show any PrP-res accumulation in the spleen (4). In terminal 48 
BSE-infected cattle no PrP-res has been detected in the spleen tissue (5, 6), indicating that the 49 
LRS is not involved in the disease pathogenesis of BSE in cattle.  However, in sheep 50 
experimentally infected with BSE, TSE infectivity and PrPSc has been identified in the peripheral 51 
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tissues including the LRS and the spleen (7, 8). In murine models, infectivity levels in the spleen 52 
tissue have been shown to have an initial increase in titre within days of inoculation that then 53 
plateaus for the remainder of the disease duration, long before infectivity is detected in the CNS 54 
(9, 10). At disease end-point, the spleen contains lower titres of infectivity than the 55 
corresponding brain tissue, regardless of the route of infection. For example, it has been shown 56 
that wild-type/139A mouse spleens contain 2-3log10 units less infectivity than the brain (11). In 57 
correlation with the infectivity data, the levels of PrP-res in the spleen of 139A infected mice 58 
were 500-fold less than those observed in the brain tissue at terminal stage of disease (11). 59 
Further studies identified that the level of PrP-res was 200-300 fold less in the spleen than in the 60 
brain of mice infected with a mouse-adapted strain of Gerstmann-Sträussler-Scheinker (GSS) 61 
originating from Fukuoka-1 GSS case (12).  62 
If peripheral levels of infectivity are equally low in all cases of TSE disease, the current safety 63 
measures in place for removal of specified risk material should prevent any infected material 64 
from entering the food chain for human consumption. However, a number of natural and 65 
experimental TSE isolates have been identified that do not have the expected association 66 
between levels of TSE infectivity and PrP-res in all tissues (2, 3, 13-15). Indeed one study of 67 
atypical scrapie in sheep identified the presence of high levels of TSE infectivity in the spleen 68 
tissue, despite the absence of abnormal PrP (13). Given that the majority of current diagnostic 69 
tests rely on the presence of PrP-res as indicative of TSE disease, disease cases and tissues where 70 
PrP-res is absent may be falsely identified as negative. Further, the disparity between PrP-res and 71 
TSE infectivity levels may result in an underestimation of infectivity levels that are present in 72 
peripheral tissues that are allowed to enter the food chain, increasing the potential for zoonotic 73 
transfer.  74 
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We have previously identified a unique mouse model of infectious TSE disease that highlights 75 
the discrepancy between PrP-res levels and corresponding TSE infectious titres (14, 16, 17). 76 
Previous work has performed extensive characterisation of the relationship between PrP-res and 77 
TSE infectivity in the brain tissue of these disease models. Here we investigate the relationship 78 
between PrP-res and TSE infectivity within the peripheral spleen tissue of these mice using both 79 
biochemical analyses and mouse bioassay, and demonstrate that extremely high levels of 80 
infectivity can be present in peripheral tissue without a corresponding increase in PrP-res. If 81 
peripheral tissues can be as infectious as brain tissue this could represent an increased risk to 82 
food safety. Indeed if the correct combination of host species, PrP genotype and strain of agent 83 
was to occur naturally that resulted in high peripheral infectivity, infected peripheral tissue could 84 
have the potential to enter the food chain.   85 
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MATERIALS AND METHODS 86 
Ethics Statement 87 
All experimental protocols were submitted to the Local Ethical Review Committee for approval 88 
before mice were inoculated. All experiments were performed under license and in accordance 89 
with the UK Home Office Regulations (Animals (Scientific Procedures) Act of 1986). 90 
Primary transmission to 101LL transgenic mice 91 
Inbred gene-targeted transgenic mouse line 101LL and the wild-type 129/Ola control line have 92 
been previously described (16). 101LL/GSS tissues were produced by inoculation of 101LL 93 
mice with 1% (w/v) brain homogenate from the frontal cortex of a P102L GSS brain that had 94 
confirmed clinical GSS disease and abundant PrP-res detectable by immunoblot (Provided by 95 
Prof J Ironside, National CJD Surveillance and Research Unit (NCJDSRU), Edinburgh, UK). 96 
101LL/263K tissues were produced by inoculation of 101LL transgenic mice with 1% (w/v) 97 
brain homogenate from a 263K-infected hamster. As P102L GSS and 263K do not transmit 98 
efficiently to wild type mice (16, 17) alternative controls were selected to provide tissue from 99 
models in which the relationship between PrPSc and infectivity in the periphery had been 100 
previously examined (ME7 and 79A mouse adapted scrapie).  101 
Clinical assessment and vacuolation scoring 102 
Mice were assessed for the presence of clinical disease as previously described (18) and were 103 
culled by cervical dislocation when either a clinical TSE disease or an inter-current illness was 104 
observed. All experiments were performed under license and in accordance with the UK Home 105 
Office Regulations (Animals (Scientific Procedures) Act of 1986). Brain and spleen tissue was 106 
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recovered at post-mortem for biochemical and immunohistochemical analysis. Half-brain 107 
sections (6µm) were stained using haematoxylin and eosin and the abundance of TSE-related 108 
vacuolation was assessed at nine grey-matter regions (medulla, cerebellum, superior colliculus, 109 
hypothalamus, thalamus, hippocampus, septum, retrospinal cortex, cingulated and motor cortex) 110 
and three regions of white matter (cerebellar white matter, midbrain white matter and cerebral 111 
peduncle) as described previously (10). DNA was extraction from tail tissue that was taken post 112 
mortem. PCR and restriction enzyme digestion was performed as previously described (16) to 113 
confirm the presence of the P101L mutation.  114 
Sub-passage inoculations 115 
Inocula were prepared from the brains and spleens of two 101LL/GSS mice (designated 116 
101LL/GSS(a) and 101LL/GSS(b)) and two 101LL/263K mice (designated 101LL/263K(c) and 117 
101LL/263K(d)) that all had confirmed clinical TSE disease with associated TSE-vacuolar 118 
pathology. Inoculum was prepared from a wild-type/79A mouse brain and spleen tissue as 119 
controls (designated wild-type/79A(e)). A 10% (w/v) homogenate of each tissue was prepared in 120 
sterile saline and was used to produce a dilution series of 10-2, 10-3 and 10-4 for each 121 
homogenate. Utilising previous data (14) it was hypothesised that a 10-4 dilution of brain 122 
homogenate would produce a 100% attack rate. Given the expected 2-3log10 difference in TSE 123 
infectivity titres between brain and spleen tissues in murine models (11), the inoculation of these 124 
three dilutions was predicted to allow the identification of difference in incubation period 125 
between tissues, and provide an estimation in difference in titre. Each dilution (20µl) was 126 
inoculated intra-cerebrally under anaesthesia into groups of 101LL mice for 101LL/GSS and 127 
101LL/263K inocula and wild-type 129/Ola mice for wild-type/79A inocula. Dilutions of brain 128 
homogenate were inoculated into groups of 6 mice at 10-2 and 10-3 dilutions and 8 mice at 10-4 129 
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dilution. Dilutions of spleen homogenate were inoculated into groups of 6 mice at 10-2 dilution 130 
and 8 mice at 10-3 and 10-4 dilution due to the predicted lower titres. 131 
Immunohistochemistry to detect PrP deposition 132 
Immunohistochemistry was performed to detect PrP deposition in the brain tissue. Briefly, 133 
following fixation in 10% formal saline, brains were treated for 1.5 hours in 98% formic acid, 134 
dissected and embedded in paraffin. Sections (6µm) of brain tissue were hydrated, autoclaved for 135 
15 minutes at 121˚C and incubated in 98% formic acid for 5 minutes to expose the PrP epitopes. 136 
Sections were incubated in 1% hydrogen peroxide/methanol and washed in 0.2% BSA/PBS. 137 
Sections were blocked with normal goat serum, incubated overnight in anti-PrP monoclonal 138 
antibody 6H4 (Prionics), (0.5µg/ml) and then with secondary anti-mouse biotinylated antibody 139 
(Jacksons Immuno Research Laboratories) (2µg/ml) for 1 hour. Sections were processed using 140 
the ABC Elite kit (Vector Laboratories) and the signal was visualised by a reaction with 141 
hydrogen perozidize-activated diaminobenzidine.  142 
Precipitation of PrP-res with NaPTA from primary spleen tissue 143 
Sodium phosphotungstic acid (NaPTA) precipitation has previously been shown to increase the 144 
sensitivity of immunoblotting for the detection of PrPSc (19). All incubations were performed at 145 
37˚C with agitation. Briefly, spleen tissue from terminal animals was homogenised in 0.1M Tris-146 
HCl (pH7.4) to a 10% (w/v) homogenate with a glass dounce homogeniser. Cellular debris was 147 
removed through centrifugation at 1000 rpm for 5 minutes. An equal volume of 2% 148 
Sarkosyl/0.1M Tris-HCl was added to the supernatant and incubated for 10 minutes. 149 
Homogenates were digested with 50µg/ml PK for 1 hour. Digestion was stopped by the addition 150 
of phenylmethylsulfonyl fluoride to 2mM. PrP-res was selectively precipitated with 0.3% (w/v) 151 
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NaPTA for 20 minutes. Homogenates were centrifuged 15,400g for 30 minutes. Pellets were 152 
washed with 83mM EDTA, 0.1% Sarkosyl/0.1M Tris-HCl and a further 30 minutes 153 
centrifugation (15,400g) produced the PrP-res pellet that was re-suspended in the appropriate 154 
volume of tris-glycine sample buffer (Invitrogen) according to the starting weight of the tissue.  155 
Precipitation of PrP-res with NaPTA from residual inocula and brain tissue of recipient mice 156 
All incubations were performed at 37˚C with agitation to allow precipitation of PrP-res from 157 
residual inocula. Briefly, to a 50µl aliquot of each 10% (w/v) homogenate, 0.1M magnesium 158 
chloride was added and incubated for 15 minutes. An equal volume of 4% Sarkosyl/0.1M Tris-159 
HCl was added to the supernatant and incubated for 5 minutes. Homogenates were digested with 160 
50µg/ml PK for 1 hour and precipitation of PrP-res with NaPTA performed as described for 161 
spleen tissues. The PrP-res pellet was re-suspended in 15µl tris-glycine sample buffer 162 
(Invitrogen) according to the starting weight of the tissue.  163 
Immunoblotting of PrP-res 164 
PrP-res pellets produced from NaPTA precipitation were diluted as described in the text. 165 
Samples were loaded on 12% tris/glycine polyacrylamide gels (Invitrogen) and separated by 166 
SDS-PAGE. Separated proteins were transferred onto a polyvinylidenedifluoride membrane by 167 
the semi-dry transfer system (BIO-RAD). PrP was detected with monoclonal antibody 8H4 168 
(Sigma), using chemiluminescent solution (West Dura ECL substrate, Pierce) with images 169 
captured onto x-ray film.   170 
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RESULTS 171 
Low levels of PrP-res in the spleen tissue of 101LL/GSS and 101LL/263K mice.  172 
Spleens were harvested at cull from several 101LL transgenic mice that had been inoculated with 173 
P102L GSS or hamster 263K scrapie. All spleens selected for analysis were from mice which 174 
showed clinical signs of TSE disease and confirmed vacuolar pathology, but had low levels of 175 
PrP deposition by immunohistochemical analysis in the brain tissue. The levels of PrP-res in the 176 
spleens of infected mice were investigated to determine if PrP conversion and therefore 177 
replication of infectivity was occurring in the spleen tissue of these unique disease models. It has 178 
previously been shown that it is necessary to concentrate the spleen material in order to detect 179 
disease-associated forms of PrP (20) and to minimise IgG cross-reactivity during the immunoblot 180 
procedure. Therefore in these studies, PrP-res in spleen tissue was precipitated using sodium 181 
phosphotungstic acid (NaPTA) (21) to concentrate the PrP-res present for detection by 182 
immunoblotting. Analysis of the PK digested, NaPTA precipitated material identified a variation 183 
in the level of PrP-res between individual spleens (Figure 1A). However, the level of PrP-res in 184 
some 101LL/GSS and 101LL/263K spleens appeared to be lower than the level of PrP-res in the 185 
wild-type/ME7 spleens from which PrP-res was isolated as a control (Figure 1A). In order to 186 
confirm the difference in levels, doubling dilutions of the PK digested, NaPTA precipitated 187 
material from 101LL/GSS and 101LL/263K and a wild-type/ME7 spleen were analysed to 188 
determine the minimum tissue equivalent at which PrP-res could be detected with a semi-189 
quantitative immunoblot (Figure 1B). 101LL/GSS spleens were shown to contain PrP-res at a 190 
level similar to the PrP-res levels in a wild-type/ME7 spleen albeit with a lighter band intensity. 191 
101LL/263K spleens contained PrP-res present at a level two fold lower than that observed in the 192 
wild-type/ME7 spleens. Importantly of all the spleen tissue analysed, 3/20 101LL/GSS mice and 193 
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1/12 101LL/263K mice analysed contained no detectable PrP-res even with NaPTA 194 
precipitation.  195 
Brain and spleen tissues show equivalent high levels of infectivity in 101LL/GSS and 196 
101LL/263K mice.  197 
In order to confirm the presence of infectivity in spleen tissue and compare the levels of 198 
infectivity present in brain and spleen from the same mouse, 10% (w/v) homogenates of a brain 199 
and spleen from two 101LL/GSS and two 101LL/263K mice were prepared and used to produce 200 
a dilution series (10-2, 10-3 and 10-4) for inoculation. 101LL/GSS and 101LL/263K brain and 201 
spleen homogenates were inoculated into groups of 101LL transgenic mice. As both P102L GSS 202 
and hamster 263K scrapie had been shown previously to be poorly transmissible to wild type 203 
mice (16, 17), brain and spleen homogenates from murine 79A scrapie were inoculated as 204 
controls. Average incubation periods to disease were similar for each brain and spleen inocula 205 
pair from 101LL/GSS and 101LL/263K mice (Figure 2). No statistical differences (Student’s t-206 
test) were observed between the average incubation periods to disease at each dilution for 207 
101LL/263K. Although no statistical differences between incubation periods were observed for 208 
the majority of dilutions of 101LL/GSS, the two exceptions were 101LL/GSS(a) 10-3 dilution of 209 
brain homogenate that had a significantly (p-value 8.3x10-5) shorter incubation period to disease 210 
than the spleen homogenate at the same dilution, and 101LL/GSS(b) 10-2 dilution that had a 211 
significantly (p-value 5.6x10-4) shorter incubation period to disease from the brain homogenate 212 
than the spleen homogenate. However, these significant differences were not consistent and were 213 
not observed for all dilutions of the same inoculum. Overall the data (Figure 2) show that the 214 
brain and spleen incubation periods were similar in 101LL/GSS and 101LL/263K tissues. In 215 
comparison, significantly different incubation periods to disease were observed between brain 216 
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and spleen homogenates from wild-type/79A mice at each dilution. The average incubation 217 
period to disease for the wild-type/79A spleen homogenates was 30-40 days longer than the 218 
average incubation period to disease with the corresponding brain homogenates. 219 
Analysis of PrP-res levels in residual inocula 220 
Given the similar infectivity levels between the brain and spleen homogenate, we analysed the 221 
levels of PrP-res present in the residual inocula. Little or no PrP-res was present in the residual 222 
brain homogenate from 101LL/GSS and 101LL/263K inocula samples when standard PK 223 
digestion and immunoblotting was performed on 10% homogenates (data not shown). NaPTA 224 
precipitation was required to detect PrP-res levels in the residual spleen homogenate by 225 
increasing the sensitivity levels of detection (19, 20). A low level of PrP-res was present in the 226 
101LL/GSS(a) & (b) residual spleen homogenates (Figure 3B). NaPTA precipitation of the 227 
residual brain tissue homogenates (Figure 3A) indicated a similar low level of PrP-res was 228 
present in 101LL/GSS(a) & (b) and 101LL/263K(c). However, it is important to highlight that no 229 
PrP-res was present following NaPTA precipitation of residual brain or spleen homogenate from 230 
101LL/263K(d) despite this inoculum causing infectious TSE disease in the mice that received 231 
the inocula. Indeed no difference was observed in incubation period between 101LL/263K(c) 232 
that contained low levels of PrP-res and 101LL/263K(d) that did not contain detectable PrP-res.  233 
Strain properties are maintained on sub-passage with different levels of vacuolation and PrP 234 
deposition 235 
The lesion profiles produced from 101LL/GSS and 101LL/263K brain and spleen inoculations 236 
(Figure 4) followed a similar pattern varying only in level of vacuolation with higher levels of 237 
vacuolation observed from inoculation of the spleen tissue compared to the brain tissue. 238 
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Immunohistochemical analysis of the PrP deposition patterns (Figure 5) indicated that PrP 239 
deposition targeted similar areas in the recipient brains irrespective of the tissue source of the 240 
inoculum. In 101LL/GSS mice, PrP deposition was targeted to the hippocampus, thalamus and 241 
the midbrain. In cases with heavier deposition, PrP was also observed in the medulla and 242 
occasionally the septum. However, PrP deposition observed was lighter in those mice inoculated 243 
with 101LL/GSS spleen homogenate compared to those inoculated with the 101LL/GSS brain 244 
homogenate from the same mouse. In 101LL/263K mice, PrP deposition was targeted to the 245 
hippocampus with PrP aggregates present in the corpus callosum, midbrain and medulla with 246 
similar PrP deposition levels irrespective of the tissue source of the inocula. 247 
Varying levels of PrP-res present in the 101LL/GSS recipient brains dependent on tissue type 248 
inoculated.  249 
Given the different levels of PrP deposition observed by immunohistochemistry depending on 250 
tissue source for 101LL/GSS, recipient brain tissue from animals receiving brain and spleen 251 
inocula was analysed through PK digestion, NaPTA precipitation and immunoblotting. The 252 
results (Figure 6) confirm that 101LL/GSS mice that received brain homogenate had a greater 253 
level of PrP-res than mice that received spleen homogenate. The differences in the levels of PrP-254 
res in 101LL/GSS were shown to be present in each dilution group inoculated. In contrast, the 255 
levels of PrP-res in 101LL/263K tissues were variable independent of tissue-type inoculated 256 
whilst the levels of PrP-res in wild-type/79A mice were similar irrespective of the tissue type 257 
inoculated. These results were confirmed through a number of different techniques including 258 
standard PK digestion (performed at 37˚C without the use of NaPTA) and isolation of scrapie-259 
associated fibrils (data not shown).   260 
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DISCUSSION 261 
The prion hypothesis proposes that PrPSc is the sole or main component of the infectious agent in 262 
TSE diseases. Based on the prion hypothesis, the majority of TSE diagnostic tests rely on the 263 
detection of PrP-res as indicative of TSE disease. However, recently data have shown that PrP-264 
res and TSE infectivity levels do not always correlate, with infectivity identified in tissues in 265 
which PrP-res was not detectable (2, 3, 13, 14). The involvement of the lymphoreticular system 266 
in TSE diseases is dependent upon the combination of host species, genotype and TSE agent. In 267 
the majority of murine TSE disease models, the levels of PrP-res present in the spleen are lower 268 
than those present in the brain tissue (11, 12). However, in the disease models investigated here, 269 
we have shown equally short incubation periods following sub-passage of either brain or spleen 270 
homogenate from the same mouse, indicating the presence of similar levels of infectivity in both 271 
tissues. This was in contrast to the wild-type 79A control which showed consistently extended 272 
incubation times with spleen homogenate (30-40 days) compared to brain homogenate. Based on 273 
previous data (14), we can therefore hypothesise that despite the extremely low levels of PrP-res 274 
identified in both brain and spleen of these mice following NaPTA precipitation the titre of 275 
infectivity in each tissue is similar, at approximately107-109 IU/g. Thus the spleen tissue 276 
maintains the discrepancy observed in the brain tissue of these unique disease models with high 277 
infectivity levels observed despite the presence of low levels or an absence of PrP-res. Full 278 
titration studies are currently planned to accurately establish the infectious titre in the spleen 279 
tissues of the 101LL/GSS and 101LL/263K mice. However, the initial data from this disease 280 
model prove that TSE agents can have the potential to replicate to high infectivity levels in 281 
peripheral tissues when the combination of host species, PrP genotype and TSE agent provides 282 
the correct conditions for replication of the infectious agent.  283 
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Previous studies of these disease models have shown the presence of little or no PrP-res in brain 284 
tissue, despite relatively high levels of infectivity (14, 16, 17). Further investigation here has now 285 
demonstrated the presence of low levels of PrP-res in these tissues following concentration of 286 
approximately 10mg of tissue homogenate by NaPTA precipitation. Interestingly, the levels of 287 
PrP-res detected in brain and spleen of each mouse were similar, and experiments to determine 288 
whether this is the truly infectious subpopulation of PrPSc are on-going in our laboratory. 289 
However, despite identifying similar levels of PrP-res in spleens of 101LL/GSS and 79A (Figure 290 
3), estimated levels of infectivity based on incubation times were significantly higher in 291 
101LL/GSS spleen homogenates. Moreover, 101LL/263K(d) was able to transmit disease from 292 
both the brain and spleen tissue despite the absence of PrP-res in the residual inocula of both 293 
tissues even with the inclusion of NaPTA precipitation as a concentration step to increase the 294 
sensitivity levels. Together these data support the continued lack of correlation between PrP-res 295 
levels and infectivity in these mouse models of disease. 296 
Given both 101LL/GSS and 101LL/263K had similar incubation periods to disease from both 297 
brain and spleen tissue, it can be presumed that this unexpected result was not solely due to the 298 
strain of TSE agent or compatibility at codon 101/102. Indeed, the hamster 263K scrapie strain is 299 
propagated in animals with proline at PrP codon 102 (equivalent to codon 101 in mice), and does 300 
not produce the same disease phenotype when passaged in hamsters. Therefore the disease 301 
phenotype in 101LL mice is not an intrinsic characteristic of the strain but rather due to the 302 
specific combination of host species, PrP genotype and strain of agent that allows this disease 303 
phenotype of high infectivity levels but extremely low levels of PrP-res to manifest. It is possible 304 
that this phenotype is uniquely due to the 101L mutation in the recipient mice altering disease 305 
pathogenesis or selecting a different isolate from the heterogeneous population of the infectious 306 
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agent. Further analyses of other TSE strains (e.g. ME7, 79A, 301V) in these mice (which show 307 
similar PrP-res levels to wild type mice; (22)) are planned to address this issue. 308 
Several recent studies have identified the presence of quasi-species present within individual 309 
cases of TSE disease in humans (23, 24), animals (25) and in cell-culture models (26). Indeed it 310 
has been hypothesised that sub-variants of disease-associated PrP replicate preferentially in a 311 
specific tissue type with dependence on tissue-specific host factors (25, 27). The biochemical 312 
and immunohistochemical analysis of the recipient mice from the 101LL/GSS sub-passage 313 
demonstrated that PrP-res deposition was lower in the brain tissue of mice that received the 314 
spleen homogenate inocula compared to those that received the brain homogenate inocula 315 
(Figure 6) whilst in contrast the vacuolation score in mice was greater in those that received the 316 
spleen homogenate than the brain homogenate (Figure 4). These results indicate that a potentially 317 
heterogeneous population of PrP-res was present. It is hypothesised that tissue-specific 318 
conditions supported replication of different sub-variants that upon sub-passage showed different 319 
replication efficiencies. If heterogeneous populations of PrP-res exist with variants that have 320 
different replication capabilities, a variant present in peripheral tissues may have a higher level 321 
of infectivity than the corresponding brain-derived variant. Therefore assessment of the 322 
peripheral infectivity levels from novel and emerging isolates is urgently required to ensure an 323 
accurate titre is established to maintain food safety.  324 
Together these results indicate that a form of the infectious agent may be present in this disease 325 
model that remains undetectable by current standard analysis. Given the increasing costs of 326 
bioassay to identify the presence of TSE infectivity, the majority of disease cases are being 327 
confirmed by biochemical techniques specific for the presence of PrP-res without confirmation 328 
of the presence of infectivity. This current reliance on PrP-res as indicative of TSE disease may 329 
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not detect all cases of TSE disease with the possible emergence of cases with high infectivity 330 
levels associated with low levels or an absence of PrP-res. Indeed the discovery of significant 331 
levels of TSE infectivity in the spleens from sheep infected with atypical scrapie despite the 332 
absence of PrP-res (13) indicates that this disease phenomenon can occur in natural cases of TSE 333 
disease present in the environment. .Further, a recent study by Gonzalez and colleagues 334 
highlighted the discrepancy between levels of PrP-res and TSE infectivity in sheep scrapie and 335 
sheep BSE and indicated that quantitative laboratory tests to detect disease-associated PrP could 336 
not be used to accurately predict infectious titres (28).While TSEs remain in the environment, the 337 
emergence of novel isolates, or the possibility that a known isolate could infect a different host 338 
species remains. Our data show that a combination of host species, PrP genotype and TSE isolate 339 
has the potential to occur that could produce a novel disease phenotype with high levels of TSE 340 
infectivity in the absence of PrP-res. Therefore if infectivity levels in the peripheral tissues of 341 
disease cases with low levels of PrP-res are higher than originally hypothesised from previous 342 
research into classical isolates and current biochemical tests, the emergence of a novel isolate 343 
could pose a major risk to food safety if tissues were able to enter the food chain. Together with 344 
the discrepancy between PrP-res and TSE infectivity levels presented here, the estimation of titre 345 
should not rely on the detection of PrP-res as the sole indicator of TSE disease.  346 
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Figure Legends 440 
Figure 1: PrP-res levels in 101LL/GSS and 101LL/263K spleens compared to PrP-res levels 441 
in wild-type/ME7 spleens. Spleen homogenates were PK digested, NaPTA precipitated and the 442 
samples loaded at a tissue equivalent of 15mg (A and B) or loaded a different tissue weights 443 
(mg) as indicated (C and D). PrP-res was present in 101LL/GSS (A) and 101LL/263K (B) 444 
spleens with variation between three individual spleens (lanes 1-3). ME7 spleen samples loaded 445 
as control (A; Lane 4.  B; Lanes 4 and 5). The dilution series (C and D) allowed estimation of the 446 
difference in PrP-res levels between 101LL/GSS  (C; Lanes 6-9) or 101LL/263K (D; Lanes 6-447 
10) with levels observed in wild-type/ME7 spleens (C and D lanes 1-5). Normal brain 448 
homogenate was loaded on each blot to provide PrPC band as internal control. Blots probed with 449 
mAb 8H4 and exposed for 5 minutes.  450 
 451 
Figure 2: Similar average incubation periods to disease from brain and spleen transmissions 452 
from 101LL/GSS and 101LL/263K. In comparison, the average incubation periods for 453 
transmission of brain and spleen tissue from wild-type mice were statistically different, with 454 
longer incubation periods produced from inoculation with spleen tissue (blue bars). Statistics 455 
calculated with student’s two-tailed t-test with p-values of 2.88x10-5, 3.66x10-6, and 1.08x10-8 456 
for 10-2, 10-3 and 10-4 groups respectively for wild-type/79A transmission. One 101LL/GSS(a) 457 
dilution, 10-3 produced a significant difference (p-value 8.3x10-5) and one 101LL/GSS(b) 458 
dilution, 10-2 produced a significant difference (p-value 5.6x10-4). 459 
 460 
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Figure 3: Low PrP-res levels in (A) brain and (B) spleen residual inocula identified by 461 
NaPTA precipitation. In contrast PrP-res was present in wild-type/79A brain and spleen 462 
residual homogenates. Residual homogenates were PK digested, NaPTA precipitated. Samples 463 
were loaded at a wet weight tissue equivalent of 10mg, proteins separated by SDS-PAGE. 464 
Immunoblots probed with mAb 8H4 and exposed for 10 minutes. 465 
 466 
Figure 4: Similar lesion profiles with slight variation in vacuolation levels dependent on the 467 
tissue type inoculated. Lesion profiles were similar for both brain and spleen tissue inocula in 468 
(A) 101LL/GSS(a), (B) 101LL/GSS (b), (C)101LL/263K(c) and (D) 101LL/263K(d) but a 469 
higher vacuolation level was observed after inoculation of the spleen tissue compared to the 470 
brain tissue. In comparison, the lesion profiles from inoculation of brain and spleen tissue from 471 
wild-type/79A mice (E) followed the same pattern with inoculation of the brain tissue producing 472 
a slightly higher vacuolation level than the spleen tissue.  473 
 474 
Figure 5: Lighter PrPSc deposition observed from inoculation of spleen homogenates 475 
compared to brain homogenates from 101LL/GSS. Similar levels of PrPSc deposition for 476 
101LL/263K irrespective of tissue inoculated. Tissues taken from mice inoculated with 10-2 477 
dilution of inocula. Immunohistochemistry performed with mAb 6H4. Hippocampus region are 478 
shown at x2 magnification in left-hand column. Brain areas containing PrPSc deposition are 479 
shown at x20 magnification.  480 
 481 
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Figure 6: PrP-res levels in recipient mouse brain vary dependent upon tissue type 482 
inoculated from 101LL/GSS mice. This phenomenon was observed from both (A) 483 
101LL/GSS(a) and 101LL/GSS(b) mice. In contrast, (B) 101LL/263K(c) and 101LL/263K(d) 484 
had variable levels of PrP-res independent of tissue-type inoculated whilst (A and B) wild-485 
type/79A recipient brains had the same level of PrP-res independent of tissue-type inoculated. 486 
Tissue homogenates were PK digested and NaPTA precipitated. Lanes 1, 2, 5, 6, 9, 10 : Brain 487 
tissue. Lanes 3, 4, 7, 8, 11, 12: Spleen tissue. Samples loaded at an equivalent of a wet tissue 488 
weight of 33mg. An uninfected brain homogenate was loaded at 10mg/ml (w/v) wet weight 489 
tissue in lane 13 as internal control. Blots probed with mAb 8H4.  490 
 491 
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